Table 1 Characteristics of Subjects
From: Dose-dependent Effect of Statin Therapy on Circulating CXCL12 Levels in Patients with Hyperlipidemia
Characteristic | No statin(n=11) | Low dose statin(n=48) | High dose statin (n=120) | p Value |
|---|---|---|---|---|
Age (years) | 65 +/- 14 | 64 +/- 11 | 60 +/- 12 | 0.489 |
Male gender | 8 (73%) | 31 (65%) | 85 (71%) | 0.707 |
Race | ||||
Caucasian | 11 (100%) | 41 (85%) | 106 (88%) | 0.398 |
African-American | 0 (0%) | 7 (15%) | 14 (12%) | 0.398 |
Hypertension* | 7 (64%) | 42 (88%) | 104 (87%) | 0.098 |
Diabetes mellitus | 4 (36%) | 11 (23%) | 39 (33%) | 0.874 |
Tobacco use | 4 (36%) | 10 (21%) | 33 (28%) | 0.730 |
Family history of CAD | 2 (18%) | 23 (48%) | 51 (43%) | 0.047 |
Prior Angina | 5 (45%) | 17 (35%) | 55 (46%) | 0.802 |
Peripheral arterial disease | 1 (9%) | 10 (21%) | 33 (28%) | 0.460 |
Congestive heart failure | 2 (18%) | 3 (6%) | 9 (8%) | 0.958 |
Myocardial infarction | 3 (27%) | 11 (23%) | 48 (40%) | 0.050 |
Prior CABG | 3 (27%) | 4 (8%) | 22 (18%) | 0.104 |
Prior PCI | 3 (27%) | 16 (33%) | 47 (40%) | 0.401 |
Prior Stroke | 0 (0%) | 3 (6%) | 18 (15%) | 0.445 |
Medications | ||||
Beta-blocker | 7 (64%) | 27 (56%) | 84 (71%) | 0.183 |
ACE inhibitor | 3 (27%) | 22 (46%) | 53 (45%) | 0.397 |
Aspirin | 9 (82%) | 36 (75%) | 102 (86%) | 0.678 |
Insulin | 2 (18%) | 5 (10%) | 13 (11%) | 0.652 |
Oral hypoglycemic | 1 (9%) | 7 (15%) | 16 (14%) | 0.869 |
Calcium channel blocker | 2 (18%) | 10 (21%) | 15 (13%) | 0.681 |
Clopidogrel | 4 (36%) | 11 (23%) | 30 (25%) | 0.393 |
Lipid panel (mmol/L) | ||||
Total cholesterol | 160 [134-161] | 157 [136-177] | 161 [135-200] | 0.593 |
Low density lipoprotein | 88 [81-106] | 95 [80-112] | 92 [74-131] | 0.815 |
High density lipoprotein | 43 [37-51] | 38 [33-47] | 38 [32-44] | 0.128 |
Triglycerides | 89 [55-131] | 111 [85-199] | 132 [100-194] | 0.098 |
Angiographic data | ||||
Obstructive CAD † | 10 (91%) | 39 (81%) | 106 (88%) | 0.434 |
Non-obstructive CAD | 1 (9%) | 8 (17%) | 19 (16%) | 0.819 |
Presence of collaterals | 3 (27%) | 16 (67%) | 42 (60%) | 0.868 |
Cytokines (pg/mL) | ||||
CXCL1 | 10516 [2094-27454] | 4087 [899-18355] | 7709 [1749-20804] | 0.026 |
CXCL3 | 987 [288-1351] | 514 [230-1163] | 632 [215-1003] | 0.359 |
CXCL5 | 5820 [4041-15103] | 5127 [2326-8607] | 5820 [2985-9245] | 0.290 |
CXCL8 | 741 [517-1391] | 751 [367-1441] | 758 [345-1664] | 0.884 |
CXCL9 | 4133 [68-16835] | 3421 [297-7749] | 3558 [392-7741] | 0.890 |
CXCL10 | 1552 [922-2075] | 922 [587-1362] | 901 [587-1670] | 0.117 |
CXCL11 | 7577 [2920-9914] | 5072 [2711-7724] | 4449 [2786-7500] | 0.259 |
CXCL12 | 2316 [2255-11071] | 2362 [2016-10622] | 2189 [1968-2705] | 0.042 |
CCL2 | 131 [32-163] | 58 [39-92] | 62 [28-132] | 0.259 |
VEGF | 909 [559-3997] | 1219 [205-1991] | 957 [147-1880] | 0.678 |
IFN-γ | 472 [92-1034] | 317 [113-472] | 304 [147-525] | 0.467 |